Combined oral and topical mesalazine treatment for extensive ulcerative colitis.
BACKGROUND
A 32-year-old white Jewish woman was referred to our clinic in October 2002 for a second opinion on the management of her active extensive ulcerative colitis that did not respond to oral mesalazine (mesalamine) 3.6 g/day. The severity of symptoms had affected her plans to have children.


METHODS
Laboratory investigations, including perinuclear antineutrophil cytoplasmic antibodies and antibodies to Saccharomyces cerevisiae, stool cultures, and sigmoidoscopy to 40 cm from the rectum, with biopsies.


METHODS
Moderate-to-severe active extensive ulcerative colitis, unresponsive to mesalazine at 3.6 g/day.


RESULTS
Oral mesalazine 4.8 g/day and 4 g mesalazine enemas nightly.
Moss
Alan C
AC
Center for Inflammatory Bowel Disease, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. amoss@bidmc.harvard.edu
Cheifetz
Adam S
AS
Peppercorn
Mark A
MA